New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
10:25 EDTBSX, BSX, LLY, LLY, LH, LH, GEVA, GEVA, ACT, ACT, Q, Q, BIO, BIO, HSIC, HSIC, ALOG, ALOG, SIAL, SIAL, WMGI, WMGI, AGIO, AGIO, OPHT, OPHTJPMorgan to host a conference
32nd Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 13 at 10:30 am; not all presentations may be webcasted. Webcast Link
News For OPHT;AGIO;WMGI;SIAL;ALOG;HSIC;BIO;Q;ACT;GEVA;LH;LLY;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 28, 2015
06:34 EDTAGIOCalithera Biosciences price target raised to $30 from $15 at Citigroup
Subscribe for More Information
05:58 EDTAGIOAgios Pharmaceuticals downgraded to Neutral from Buy at Citigroup
Subscribe for More Information
January 27, 2015
17:04 EDTACTShire granted petitiion by U.S. Supreme Court
Subscribe for More Information
January 26, 2015
17:34 EDTACTActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
08:52 EDTBSXCourt ruling likely to be positive for Boston Scientific, says Bernstein
Subscribe for More Information
07:36 EDTGEVASynageva announecs dosing of patients concerned with SBC-103 in Phase 1/2 study
Synageva announced dosing with SBC-103 in patients with mucopolysaccharidosis IIIB has begun as part of a Phase 1/2 study. In addition, the FDA recently granted SBC-103 Fast Track designation. The trial will enroll approximately nine patients, two years of age or greater but less than 12 years of age, with definitive diagnosis of MPS IIIB and developmental delay. Patients will be treated in one of three different dosing cohorts with every other week intravenous administrations of SBC-103 for 24 weeks. Patients who meet qualifying criteria may continue therapy with SBC-103 for an extended treatment period that will last up to 128 weeks. The primary endpoint of the trial is safety and tolerability of intravenous administration of SBC-103 in patients with MPS IIIB. The study will also determine the effects of dosing with SBC-103 on the onset, magnitude, and reversibility of changes in levels of total HS in cerebral spinal fluid, serum, and urine as well as measure the effects of neurocognitive and developmental function and change in brain structures as assessed by magnetic resonance imaging. Exploratory biomarkers, SBC-103 concentration in CSF, MPS IIIB disease characteristics, symptoms, and quality of life will also be measured.
07:34 EDTACTActavis to acquire Auden Mckenzie for GBP306M accretive in FY15
Subscribe for More Information
January 25, 2015
20:22 EDTLHA small miss for LabCorp could cause a share drop, Barron's says
Subscribe for More Information
January 23, 2015
14:02 EDTBSXJPMorgan reports 5.7% passive stake in Boston Scientific
07:32 EDTLHCharles River Labs upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Charles River Labs (CRL) to Outperform citing improving demand for early-stage development services as well as opportunity for share gains due to Covance’s (CVD) pending merger with LabCorp (LH).
January 22, 2015
07:31 EDTBSXBoston Scientific damages in case likely to be manageable, says Wells Fargo
Subscribe for More Information
07:10 EDTSIALSigma-Aldrich and Belgium's VIB partner for research tool development
Subscribe for More Information
05:57 EDTACTActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
05:47 EDTBSXStocks with implied volatility movement; BSX T
Stocks with implied volatility movement; Boston Scientific (BSX) 49, AT&T (T) 20 according to iVolatility.
January 21, 2015
12:30 EDTACTGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
07:22 EDTACTActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
11:13 EDTALOGAnalogic backs FY15 revenue growth in mid-single digits, consensus $545.43M
Sees growth flat in 1H15, strong in 2H15. Continues to expect full year adjusted operating margin improvement of 1-2 points. Expects Medical Imaging market revenue to be flat. Expects Ultrasound to grow double digits. Expects Security and Detection to growth double-digits on strong backlog. Guidance from presentation slides.
08:21 EDTLHLabCorp upgraded to Buy from Hold at Evercore ISI
Subscribe for More Information
05:34 EDTACTActavis reports positive Phase III results for cariprazine
Gedeon Richter and Actavis announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses in the cariprazine group versus 47 relapses in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use